{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:37:15Z","timestamp":1790685435736,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T00:00:00Z","timestamp":1591747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T00:00:00Z","timestamp":1591747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Androgen deprivation therapy (ADT) is widely used in the treatment of testosterone-dependent prostate carcinomas. ADT often increases plasma LDL and HDL cholesterol and triglycerides. The aim was to test whether ADT changes the transfer of lipids to HDL, an important aspect of this metabolism and HDL protective functions, and related parameters.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Sixteen volunteers with advanced prostate carcinoma submitted to pharmacological ADT or orchiectomy had plasma collected shortly before and after 6\u2009months of ADT. In vitro transfer of lipids to HDL was performed by incubating plasma with donor emulsion containing radioactive lipids by 1\u2009h at 37\u2009\u00b0C. After chemical precipitation of apolipoprotein B-containing lipoprotein, the radioactivity of HDL fraction was counted.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>ADT reduced testosterone to nearly undetectable levels and markedly diminished PSA. ADT increased the body weight but glycemia, triglycerides, LDL and HDL cholesterol, HDL lipid composition and CETP concentration were unchanged. However, ADT increased the plasma unesterified cholesterol concentration (48\u2009\u00b1\u200912 vs 56\u2009\u00b1\u200912\u2009mg\/dL, <jats:italic>p<\/jats:italic>\u2009=\u20090.019) and LCAT concentration (7.15\u2009\u00b1\u20091.81 vs 8.01\u2009\u00b1\u20091.55\u03bcg\/mL, <jats:italic>p<\/jats:italic>\u2009=\u20090.020). Transfer of unesterified (7.32\u2009\u00b1\u20091.09 vs 8.18\u2009\u00b1\u20091.52%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05) and esterified cholesterol (6.15\u2009\u00b1\u20090.69 vs 6.94\u2009\u00b1\u20091.29%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01) and of triglycerides (6.37\u2009\u00b1\u20090.43 vs 7.18\u2009\u00b1\u20090.91%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) to HDL were increased after ADT. Phospholipid transfer was unchanged.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Increase in transfer of unesterified and esterified cholesterol protects against cardiovascular disease, as shown previously, and increased LCAT favors cholesterol esterification and facilitates the reverse cholesterol transport. Thus, our results suggest that ADT may offer anti-atherosclerosis protection by improving HDL functional properties. This could counteract, at least partially, the eventual worse effects on plasma lipids.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12944-020-01305-8","type":"journal-article","created":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T09:03:03Z","timestamp":1591779783000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Androgen deprivation therapy improves the in vitro capacity of high-density lipoprotein (HDL) to receive cholesterol and other lipids in patients with prostate carcinoma"],"prefix":"10.1186","volume":"19","author":[{"given":"Cicero P.","family":"Albuquerque","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima R.","family":"Freitas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Elisa M.","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josefa H.","family":"Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael F.","family":"Coelho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos V.","family":"Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willian C.","family":"Nahas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Kalil Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1520-4914","authenticated-orcid":false,"given":"Raul C.","family":"Maranh\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,10]]},"reference":[{"key":"1305_CR1","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","volume":"71","author":"N Mottet","year":"2017","unstructured":"Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate Cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2017;71:618\u201329.","journal-title":"Eur Urol"},{"key":"1305_CR2","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/S0140-6736(14)61947-4","volume":"387","author":"G Attard","year":"2016","unstructured":"Attard G, Parker C, Eeles RA, et al. Prostate cancer. Lancet. 2016;387:70\u201382.","journal-title":"Lancet."},{"key":"1305_CR3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/iju.13473","volume":"25","author":"K Mitsuzuka","year":"2018","unstructured":"Mitsuzuka K, Arai Y. Metabolic changes in patients with prostate cancer during androgen deprivation therapy. Int J Urol. 2018;25:45\u201353.","journal-title":"Int J Urol"},{"key":"1305_CR4","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/nrcardio.2015.124","volume":"13","author":"RS Rosenson","year":"2016","unstructured":"Rosenson RS, Brewer HB Jr, Ansell BJ, et al. Dysfunctional HDL and atherosclerotic cardiovascular disease. Nat Rev Cardiol. 2016;13:48\u201360.","journal-title":"Nat Rev Cardiol"},{"key":"1305_CR5","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1001\/jamacardio.2016.2050","volume":"1","author":"G Chen","year":"2016","unstructured":"Chen G, Levy D. Contributions of the Framingham heart study to the epidemiology of coronary heart disease. JAMA Cardiol. 2016;1:825\u201330.","journal-title":"JAMA Cardiol"},{"key":"1305_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/B978-0-12-800141-7.00001-2","volume":"65","author":"RC Maranh\u00e3o","year":"2014","unstructured":"Maranh\u00e3o RC, Freitas FR. HDL metabolism and atheroprotection: predictive value of lipid transfers. Adv Clin Chem. 2014;65:1\u201341.","journal-title":"Adv Clin Chem"},{"key":"1305_CR7","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s11745-009-3342-2","volume":"44","author":"AC Lo Prete","year":"2009","unstructured":"Lo Prete AC, Dina CH, Azevedo CH, et al. In vitro simultaneous transfer of lipids to HDL in coronary artery disease and in statin treatment. Lipids. 2009;44:917\u201324.","journal-title":"Lipids."},{"key":"1305_CR8","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","volume":"18","author":"WT Friedewald","year":"1972","unstructured":"Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499\u2013502.","journal-title":"Clin Chem"},{"key":"1305_CR9","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1161\/01.RES.4.2.129","volume":"4","author":"JH Bragdon","year":"1956","unstructured":"Bragdon JH, Eder HA, Gould RG, et al. Lipid nomenclature: recommendations regarding the reporting of serum lipids and lipoproteins made by the committee on lipid and lipoprotein nomenclature of the American Society for the Study of arteriosclerosis. Circ Res. 1956;4:129.","journal-title":"Circ Res"},{"key":"1305_CR10","doi-asserted-by":"crossref","first-page":"8216","DOI":"10.1016\/S0021-9258(18)34320-5","volume":"257","author":"GS Ginsburg","year":"1982","unstructured":"Ginsburg GS, Ginsburg GS, Atikinson D. Microemulsions of phospholipids and cholesterol esters: protein-free models of low density lipoprotein. J Biol Chem. 1982;257:8216\u201327.","journal-title":"J Biol Chem"},{"key":"1305_CR11","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/BF02535988","volume":"28","author":"RC Maranh\u00e3o","year":"1993","unstructured":"Maranh\u00e3o RC, Cesar TB, Pedroso-Mariani SR, et al. Metabolic behavior in rats of a non protein microemulsion resembling low-density lipoprotein. Lipids. 1993;28:691\u20136.","journal-title":"Lipids."},{"key":"1305_CR12","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1042\/cs1040195","volume":"104","author":"F Dockery","year":"2003","unstructured":"Dockery F, Bulpitt CJ, Agarwal S, et al. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (Lond). 2003;104:195\u2013201.","journal-title":"Clin Sci (Lond)"},{"key":"1305_CR13","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.urology.2007.08.035","volume":"71","author":"MR Smith","year":"2008","unstructured":"Smith MR, Lee H, Fallon MA, et al. Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer. Urology. 2008;71:318\u201322.","journal-title":"Urology."},{"key":"1305_CR14","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1177\/1756287215617872","volume":"8","author":"P Zareba","year":"2016","unstructured":"Zareba P, Duivenvoorden W, Leong DP, et al. Androgen deprivation therapy and cardiovascular disease: what is the linking mechanism? Ther Adv Urol. 2016;8:118\u201329.","journal-title":"Ther Adv Urol"},{"key":"1305_CR15","doi-asserted-by":"publisher","first-page":"3979","DOI":"10.1200\/JCO.2006.05.9741","volume":"24","author":"M Braga-Basaria","year":"2006","unstructured":"Braga-Basaria M, Dobs AS, Muller DC, et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol. 2006;24:3979\u201383.","journal-title":"J Clin Oncol"},{"key":"1305_CR16","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1016\/j.juro.2014.12.086","volume":"193","author":"J Morote","year":"2015","unstructured":"Morote J, G\u00f3mez-Caama\u00f1o A, Alvarez-Ossorio JL, et al. The metabolic syndrome and its components in patients with prostate cancer on androgen deprivation therapy. J Urol. 2015;193:1963\u20139.","journal-title":"J Urol"},{"key":"1305_CR17","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/S0022-5347(01)67239-2","volume":"154","author":"LM Eri","year":"1995","unstructured":"Eri LM, Urdal P, Bechensteen AG. Effects of the luteinizing hormone-releasing hormone agonist leuprolide on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia. J Urol. 1995;154:100\u20134.","journal-title":"J Urol"},{"key":"1305_CR18","doi-asserted-by":"publisher","first-page":"696329","DOI":"10.1100\/2012\/696329","volume":"2012","author":"HS Sa\u011flam","year":"2012","unstructured":"Sa\u011flam HS, K\u00f6se O, Kumsar S, et al. Fasting blood glucose and lipid profile alterations following twelve-month androgen deprivation therapy in men with prostate cancer. Sci World J. 2012;2012:696329.","journal-title":"Sci World J"},{"key":"1305_CR19","doi-asserted-by":"publisher","first-page":"S34","DOI":"10.1016\/j.juro.2012.11.017","volume":"189","author":"PJ Saylor","year":"2013","unstructured":"Saylor PJ, Smith MR. Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol. 2013;189:S34\u201342.","journal-title":"J Urol"},{"key":"1305_CR20","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1159\/000342814","volume":"90","author":"C Salvador","year":"2013","unstructured":"Salvador C, Planas J, Agreda F, et al. Analysis of the lipid profile and atherogenic risk during androgen deprivation therapy in prostate cancer patients. Urol Int. 2013;90:41\u20134.","journal-title":"Urol Int"},{"key":"1305_CR21","first-page":"1610","volume":"77","author":"SM Haffner","year":"1993","unstructured":"Haffner SM, Mykk\u00e4nen L, Valdez RA, et al. Relationship of sex hormones to lipids and lipoproteins in nondiabetic men. J Clin Endocrinol Metab. 1993;77:1610\u20135.","journal-title":"J Clin Endocrinol Metab"},{"key":"1305_CR22","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1002\/cncr.23440","volume":"112","author":"MR Smith","year":"2008","unstructured":"Smith MR, Lee H, McGovern F, et al. Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome. Cancer. 2008;112:2188\u201394.","journal-title":"Cancer."},{"key":"1305_CR23","doi-asserted-by":"crossref","unstructured":"Maranh\u00e3o RC, Freitas FR, Strunz CM, et al. Lipid transfers to HDL are predictors of precocious clinical coronary heart disease. Clin Chim Acta. 2012;413:502\u20135.","DOI":"10.1016\/j.cca.2011.11.011"},{"key":"1305_CR24","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12933-015-0270-8","volume":"14","author":"MC Sprandel","year":"2015","unstructured":"Sprandel MC, Hueb WA, Segre A, et al. Alterations in lipid transfers to HDL associated with the presence of coronary artery disease in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2015;14:107\u201315.","journal-title":"Cardiovasc Diabetol"},{"key":"1305_CR25","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/j.healun.2009.05.024","volume":"28","author":"CG Puk","year":"2009","unstructured":"Puk CG, Bocchi EA, Lo Prete AC, et al. Transfer of cholesterol and other lipids from a lipid nanoemulsion to high-density lipoprotein in heart transplant patients. J Heart Lung Transplant. 2009;28:1075\u201380.","journal-title":"J Heart Lung Transplant"},{"key":"1305_CR26","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jacl.2014.10.004","volume":"9","author":"FS Pozzi","year":"2015","unstructured":"Pozzi FS, Maranh\u00e3o RC, Guedes LK, et al. Plasma kinetics of an LDL-like non-protein nanoemulsion and transfer of lipids to high-density lipoprotein (HDL) in patients with rheumatoid arthritis. J Clin Lipidol. 2015;9:72\u201380.","journal-title":"J Clin Lipidol"},{"key":"1305_CR27","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s11745-017-4274-x","volume":"52","author":"WPC de Oliveira","year":"2017","unstructured":"de Oliveira WPC, Tavoni TM, Freitas FR, et al. Lipid transfers to HDL are diminished in long-term bedridden patients: association with low HDL-cholesterol and increased inflammatory markers. Lipids. 2017;52:703\u20139.","journal-title":"Lipids."},{"key":"1305_CR28","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.cca.2017.12.031","volume":"478","author":"AAS Soares","year":"2018","unstructured":"Soares AAS, Tavoni TM, de Faria EC, et al. HDL acceptor capacities for cholesterol efflux from macrophages and lipid transfer are both acutely reduced after myocardial infarction. Clin Chim Acta. 2018;478:51\u20136.","journal-title":"Clin Chim Acta"},{"key":"1305_CR29","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1111\/jgs.13500","volume":"63","author":"AL Bachi","year":"2015","unstructured":"Bachi AL, Rocha GA. SprandelMC, et al. exercise training improves plasma lipid and inflammatory profiles and increases cholesterol transfer to high-density lipoprotein in elderly women. J Am Geriatr Soc. 2015;63:1247\u20139.","journal-title":"J Am Geriatr Soc"},{"key":"1305_CR30","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1016\/j.amjcard.2010.12.014","volume":"107","author":"A Casella-Filho","year":"2011","unstructured":"Casella-Filho A, Chagas AC, Maranh\u00e3o RC, et al. Effect of exercise training on plasma levels and functional properties of high-density lipoprotein cholesterol in the metabolic syndrome. Am J Cardiol. 2011;107:1168\u201372.","journal-title":"Am J Cardiol"},{"issue":"4","key":"1305_CR31","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1055\/s-0034-1396863","volume":"123","author":"OG Laverdy","year":"2015","unstructured":"Laverdy OG, Hueb WA, Sprandel MC, Kalil-Filho R, Maranh\u00e3o RC. Effects of glycemic control upon serum lipids and lipid transfers to HDL in patients with type 2 diabetes mellitus: novel findings in unesterified cholesterol status. Exp Clin Endocrinol Diabetes. 2015;123(4):232\u20139.","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"1305_CR32","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1194\/jlr.M043067","volume":"55","author":"LM Estronca","year":"2014","unstructured":"Estronca LM, Filipe HA, Salvador A, et al. Homeostasis of free cholesterol in the blood: a preliminary evaluation and modeling of its passive transport. J Lipid Res. 2014;55:1033\u201343.","journal-title":"J Lipid Res"},{"key":"1305_CR33","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/S0022-2275(20)37713-0","volume":"25","author":"S Eisenberg","year":"1984","unstructured":"Eisenberg S. High density lipoprotein metabolism. J Lipid Res. 1984;25:1017\u201358.","journal-title":"J Lipid Res"},{"key":"1305_CR34","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s11883-011-0171-6","volume":"13","author":"X Rousset","year":"2011","unstructured":"Rousset X, Shamburek R, Vaisman B, Amar M, Remaley AT. Lecithin cholesterol acyltransferase: an anti- or pro-atherogenic factor? Curr Atheroscler Rep. 2011;13:249\u201356.","journal-title":"Curr Atheroscler Rep"},{"issue":"4","key":"1305_CR35","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1111\/bju.14609","volume":"123","author":"PB \u00d8stergren","year":"2019","unstructured":"\u00d8stergren PB, Kistorp C, Fode M, et al. Metabolic consequences of gonadotropin-releasing hormone agonists vs orchiectomy: a randomized clinical study. BJU Int. 2019;123(4):602\u201311.","journal-title":"BJU Int"},{"key":"1305_CR36","doi-asserted-by":"publisher","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","volume":"24","author":"NL Keating","year":"2006","unstructured":"Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24:4448\u201356.","journal-title":"J Clin Oncol"},{"key":"1305_CR37","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1001\/jamaoncol.2015.4917","volume":"2","author":"M Sun","year":"2016","unstructured":"Sun M, Choueiri TK, Hamnvik OP, et al. Comparison of gonadotropin-releasing hormone agonists and orchiectomy: effects of androgen-deprivation therapy. JAMA Oncol. 2016;2:500\u20137.","journal-title":"JAMA Oncol"},{"key":"1305_CR38","first-page":"920","volume":"72","author":"FB Thomsen","year":"2017","unstructured":"Thomsen FB, Sandin F, Garmo H, et al. Gonadotropin-releasing hormone agonists, orchiectomy, and risk of cardiovascular disease: semi-ecologic, Nationwide. Population-based Study Eur Urol. 2017;72:920\u20138.","journal-title":"Population-based Study Eur Urol"},{"key":"1305_CR39","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1155\/2013\/823849","volume":"2013","author":"JC Melvin","year":"2013","unstructured":"Melvin JC, Holmberg L, Rohrmann S, et al. Serum lipid profiles and cancer risk in the context of obesity: four meta-analyses. J Cancer Epidemiol. 2013;2013:823\u201349.","journal-title":"J Cancer Epidemiol"},{"key":"1305_CR40","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s12916-017-0976-4","volume":"15","author":"VA Katzke","year":"2017","unstructured":"Katzke VA, Sookthai D, Johnson T, et al. Blood lipids and lipoproteins in relation to incidence and mortality risks for CVD and cancer in the prospective EPIC-Heidelberg cohort. BMC Med. 2017;15:218\u201330.","journal-title":"BMC Med"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-020-01305-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12944-020-01305-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-020-01305-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T07:53:58Z","timestamp":1625126038000},"score":1,"resource":{"primary":{"URL":"https:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/s12944-020-01305-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,10]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1305"],"URL":"https:\/\/doi.org\/10.1186\/s12944-020-01305-8","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,10]]},"assertion":[{"value":"9 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed in studies involving human participants were in accordance with the Ethics Committee of the University of S\u00e3o Paulo and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare no competing interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"133"}}